The purpose of this study is to assess the absorption, metabolism, and elimination of CC-90010 and its metabolites following a single oral dose of radiolabeled CC-90010 in participants with advanced solid tumors.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Specified dose on specified days
Specified dose on specified days
Local Institution - 0002
Madrid, M, Spain
Total [14C]-radioactivity in whole blood, plasma, urine, and feces (and vomit, if applicable)
Time frame: Up to 26 Days
Cumulative elimination of total [14C]-radioactivity (as a fraction of the radioactive dose) in urine and feces (and vomit, if applicable)
Time frame: Up to 14 Days
Total [14C]-radioactivity whole blood to plasma ratios
Time frame: Up to 26 Days
Peak plasma drug concentration (Cmax)
Time frame: Up to 26 Days
Time to peak plasma drug concentration (Tmax)
Time frame: Up to 26 Days
Area under the concentration-time curve from time zero to time the time of the last measurable concentration (AUC[0-T])
Time frame: Up to 26 Days
Biotransformation of [14C]CC-90010 as [14C]-related metabolites in plasma, urine, and feces
Time frame: Up to 26 Days
Number of participants with adverse events (AEs)
Time frame: Up to 26 Months
Number of participants with physical examination abnormalities
Time frame: Up to 26 Months
Number of participants with vital sign abnormalities
Time frame: Up to 26 Months
Number of participants with electrocardiogram (ECG) abnormalities
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to 26 Months
Number of participants with clinical laboratory abnormalities
Time frame: Up to 26 Months